<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Cardiol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Curr Cardiol Rep</journal-id><journal-title-group><journal-title>Current Cardiology Reports</journal-title></journal-title-group><issn pub-type="ppub">1523-3782</issn><issn pub-type="epub">1534-3170</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410614</article-id><article-id pub-id-type="pmc">PMC12102121</article-id>
<article-id pub-id-type="publisher-id">2241</article-id><article-id pub-id-type="doi">10.1007/s11886-025-02241-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Myocardial Disease (A Abbate and M Merlo, Section Editors)</subject></subj-group></article-categories><title-group><article-title>The Impact of Cardio-Renal-Metabolic Profile in Dilated Cardiomyopathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Akbari</surname><given-names>Tamim</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hammersley</surname><given-names>Daniel J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>May</surname><given-names>Clarice Yau-Yee</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Halliday</surname><given-names>Brian P.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Prasad</surname><given-names>Sanjay K.</given-names></name><address><email>s.prasad@rbht.nhs.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00j161312</institution-id><institution-id institution-id-type="GRID">grid.420545.2</institution-id><institution>Royal Brompton and Harefield Hospitals, </institution><institution>Part of Guy&#x02019;s and St Thomas&#x02019; NHS Foundation Trust, </institution></institution-wrap>London, UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041kmwe10</institution-id><institution-id institution-id-type="GRID">grid.7445.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id><institution>National Heart and Lung Institute, Imperial College London, </institution></institution-wrap>London, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01n0k5m85</institution-id><institution-id institution-id-type="GRID">grid.429705.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0489 4320</institution-id><institution>King&#x02019;s College Hospital, NHS Foundation Trust, </institution></institution-wrap>London, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00cv4n034</institution-id><institution-id institution-id-type="GRID">grid.439338.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 1114 4366</institution-id><institution>CMR Unit, </institution><institution>Royal Brompton Hospital, </institution></institution-wrap>Sydney Street, London, SW3 6NP UK </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>27</volume><issue>1</issue><elocation-id>89</elocation-id><history><date date-type="accepted"><day>4</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose of Review</title><p id="Par1">Dilated cardiomyopathy is an important contributor to heart failure burden worldwide. With an aging population and rising multimorbidity, in this review, we describe the prevalence of metabolic syndrome and renal failure in patients with dilated cardiomyopathy and focus on common underlying mechanisms, evaluate outcomes in these patients and highlight newer therapeutic strategies.</p></sec><sec><title>Recent Findings</title><p id="Par2">A significant proportion of patients with dilated cardiomyopathy has concomitant metabolic syndrome and renal disease. This combination of multimorbidity portends worse prognosis and often presents unique challenges in treatment given the complex interplay and shared pathophysiological pathways.</p></sec><sec><title>Summary</title><p id="Par3">Optimization of the cardio-renal-metabolic profile should be a key consideration in the management of patients with dilated cardiomyopathy. Therapeutic strategies targeting common pathophysiological pathways are needed in order to improve overall outcomes.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Dilated cardiomyopathy</kwd><kwd>Heart failure</kwd><kwd>Metabolic syndrome</kwd><kwd>Obesity</kwd><kwd>Multimorbidity</kwd><kwd>Outcomes</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Heart failure (HF) is estimated to affect around 64&#x000a0;million patients worldwide with cardiomyopathies constituting 5.4&#x000a0;million cases [<xref ref-type="bibr" rid="CR1">1</xref>]. Dilated cardiomyopathy (DCM), an important underlying cause of heart failure [<xref ref-type="bibr" rid="CR2">2</xref>], is characterized by left ventricular dilatation and reduced systolic function in the absence of coronary disease or abnormal loading conditions. The true prevalence of DCM is likely underestimated and is thought to be around 1 in 250 [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>] making it one of the most common cardiomyopathies, carrying a 20% 5-year mortality [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par5">Studies have shown the co-existence of metabolic syndrome, chronic kidney disease and heart failure suggesting shared pathophysiology and multi-directional interplay (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR7">7</xref>]. In patients with heart failure 20&#x02013;30% have diabetes, 40&#x02013;50% have chronic kidney disease and 8&#x02013;16% have both, portending worse prognosis (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Given the interplay and to enable a holistic treatment approach, the term cardio-renal-metabolic syndrome has been proposed [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par6">
<fig id="Fig1"><label>Fig. 1</label><caption><p>The impact of cardio-renal-metabolic profile in dilated cardiomyopathy. Metabolic syndrome and chronic kidney disease are common in dilated cardiomyopathy and carry worse prognosis. A complex interplay underpins common pathophysiological pathways. Therapies targeting these pathways are required to interrupt the cycle and improve outcomes in dilated cardiomyopathy. <italic>Created in BioRender. Akbari</italic>,<italic> T. (2025)</italic><ext-link ext-link-type="uri" xlink:href="https://BioRender.com/n26e844">https://BioRender.com/n26e844</ext-link></p></caption><graphic xlink:href="11886_2025_2241_Fig1_HTML" id="d33e277"/></fig>
</p><p id="Par7">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Studies of outcomes in dilated cardiomyopathy with metabolic and renal disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Population (<italic>n</italic>)</th><th align="left">Follow up (median /mean)</th><th align="left">Comorbidities (% of patients)</th><th align="left">Results/Conclusion</th></tr></thead><tbody><tr><td align="left">Eda et al., 2024</td><td align="left">283 with DCM and 80 with NDLVC</td><td align="left"><p>68.8</p><p>months</p></td><td align="left"><p>DM&#x02009;=&#x02009;21.5%</p><p>HTN&#x02009;=&#x02009;41.5%</p><p>Dyslipidaemia&#x02009;=&#x02009;32.9%</p></td><td align="left">No difference in outcomes in DCM and NDLVC</td></tr><tr><td align="left">Dziewiecka et al., 2023</td><td align="left">617 DCM and 168 HNDC</td><td align="left"><p>47</p><p>months</p></td><td align="left"><p>DM&#x02009;=&#x02009;22%</p><p>HTN&#x02009;=&#x02009;41.5%</p><p>Dyslipidaemia&#x02009;=&#x02009;65%</p></td><td align="left">No difference in outcomes between DCM and HNDC</td></tr><tr><td align="left">Silverdal et al., 2022</td><td align="left">3733 DCM</td><td align="left"><p>50.4&#x02013;60</p><p>months</p></td><td align="left"><p>DM&#x02009;=&#x02009;11&#x02013;20.8%</p><p>HTN&#x02009;=&#x02009;35.8&#x02013;46.1%</p><p>CKD&#x02009;=&#x02009;1.7&#x02013;3.7%</p></td><td align="left">Diabetes associated with increased risk of outcomes (HR 1.35, 95% CI: 1.15&#x02013;1.56; <italic>p</italic>&#x02009;=&#x02009;0.0002)</td></tr><tr><td align="left">EVITA-HF, 2020</td><td align="left">323 (DCM with DM)</td><td align="left"><p>12.5</p><p>months</p></td><td align="left"><p>DM&#x02009;=&#x02009;26.7%</p><p>HTN&#x02009;=&#x02009;78.9%</p><p>CKD&#x02009;=&#x02009;34.1%</p></td><td align="left">Higher mortality in patients with DCM and diabetes as compared to DCM without diabetes (15.2% vs. 6.5%; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001)</td></tr><tr><td align="left">L&#x000f6;fman et al., 2016</td><td align="left">4939 DCM (total HF 47, 716)</td><td align="left">Not available</td><td align="left"><p>DM&#x02009;=&#x02009;32.3%</p><p>HTN&#x02009;=&#x02009;48.2%</p><p>CKD&#x02009;=&#x02009;51%</p></td><td align="left">Increasing mortality with decreasing kidney function regardless of presence of diabetes and other factors</td></tr><tr><td align="left">Karatolios et al., 2016</td><td align="left">206 DCM</td><td align="left">55.6 months</td><td align="left"><p>Not available</p><p>Median values:</p><p>BMI&#x02009;=&#x02009;27.5&#x000a0;kg/m2</p><p>BP 120/77 mmHg</p><p>eGFR&#x02009;=&#x02009;79.9&#x000a0;ml/min/1.73&#x000a0;m</p></td><td align="left">CKD associated with composite of all cause-mortality or heart transplantation (HR 2.42, 95% CI: 1.36&#x02013;4.29; <italic>p</italic>&#x02009;=&#x02009;0.003)</td></tr><tr><td align="left">&#x000d6;sterman et al., 2024</td><td align="left">27,647 with CKD</td><td align="left">Not available</td><td align="left"><p>CKD&#x02009;=&#x02009;48%</p><p>CKD&#x02009;+&#x02009;HF&#x02009;=&#x02009;13%</p><p>CKD&#x02009;+&#x02009;DM&#x02009;=&#x02009;27%</p><p>CKD&#x02009;+&#x02009;DM&#x02009;+&#x02009;HF&#x02009;=&#x02009;13%</p></td><td align="left">Highest all-cause mortality with CKD&#x02009;+&#x02009;DM&#x02009;+&#x02009;HF (HR 3.22, 95% CI: 3.05&#x02013;3.39)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: <italic>BMI</italic>&#x02009;=&#x02009;body mass index; <italic>BP</italic>&#x02009;=&#x02009;blood pressure; <italic>CKD</italic>&#x02009;=&#x02009;chronic kidney disease; <italic>DCM</italic>&#x02009;=&#x02009;dilated cardiomyopathy; <italic>DM</italic>&#x02009;=&#x02009;diabetes mellitus; <italic>eGFR</italic>&#x02009;=&#x02009;estimated glomerular filtration rate; <italic>HF</italic>&#x02009;=&#x02009;heart failure; <italic>HNDC</italic>&#x02009;=&#x02009;hypokinetic non-dilated cardiomyopathy; <italic>HTN</italic>&#x02009;=&#x02009;hypertension; <italic>NDLVC</italic>&#x02009;=&#x02009;non-dilated left ventricular cardiomyopathy</p></table-wrap-foot></table-wrap>
</p><sec id="Sec2"><title>Metabolic Syndrome and Dilated Cardiomyopathy</title><p id="Par8">Metabolic syndrome is a constellation of risk factors which includes hypertension, obesity, diabetes and dyslipidemia that collectively contribute to multiorgan damage, each represent risk factors for adverse cardiovascular outcomes. Inflammation and oxidative stress represent core pathophysiological drivers of disease in metabolic syndrome and are mediators of micro- and macrovascular damage, fibrosis, myocardial injury and adverse remodeling leading to accelerated coronary artery disease, cardiac arrhythmia and heart failure [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par9">In a recent retrospective study by Eda et al., 283 patients with DCM were evaluated with a median follow up of 68.8 months (Interquartile range; IQR 33-93.7 months). Metabolic risk factors were common as 21.5% had diabetes, 41.5% had hypertension and 32.9% had dyslipidemia [<xref ref-type="bibr" rid="CR13">13</xref>]. Similar prevalence of diabetes (22%) and hypertension (47.3%) were reported in a larger study of patients with DCM by Dziewiecka et al. (<italic>n</italic>&#x02009;=&#x02009;617) whereas dyslipidemia (65%) was present in a much larger proportion in this study [<xref ref-type="bibr" rid="CR14">14</xref>]. In a large Swedish study of almost 1.7&#x000a0;million adolescent men (median follow up 27 years), obesity was strongly associated with the risk of DCM such that for each unit increase in body mass index (BMI), there was a 15% increase in risk (Hazard Ratio; HR per unit increase in BMI 1.15, 95% confidence interval (CI): 1.14&#x02013;1.17) [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par10">The presence of metabolic factors portends worse prognosis in heart failure [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The same seems to hold true when the underlying etiology is DCM [<xref ref-type="bibr" rid="CR18">18</xref>]. In a sub-analysis of the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program which randomized 7599 with symptomatic heart failure (diabetes&#x02009;=&#x02009;28%, DCM&#x02009;=&#x02009;13.6%), diabetes was associated with a greater relative risk of cardiovascular (CV) death or HF hospitalization irrespective of ejection fraction or underlying etiology [<xref ref-type="bibr" rid="CR19">19</xref>]. In a large Swedish Registry study of recent and established DCM patients (<italic>n</italic>&#x02009;=&#x02009;3733, median follow up 5 years), presence of diabetes was an independent predictor of major adverse cardiovascular events (MACE) and associated with a 34% increased relative risk of all-cause death, heart transplantation or HF hospitalization (HR 1.34, 95% CI: 1.15&#x02013;1.56; <italic>p</italic>&#x02009;=&#x02009;0.0002) as compared with DCM patients without diabetes [<xref ref-type="bibr" rid="CR20">20</xref>]. Interestingly, the increase in mortality with diabetes in DCM is observed independently of ischaemic heart disease. In the large multicenter EVITA-HF registry (16 centres, <italic>n</italic>&#x02009;=&#x02009;4,101), mortality in patients with diabetes and DCM (<italic>n</italic>&#x02009;=&#x02009;323) was more than double (15.2%) that of DCM patients without diabetes (6.5%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>n</italic>&#x02009;=&#x02009;885) [<xref ref-type="bibr" rid="CR21">21</xref>]. This along with other studies suggest mechanisms other than accelerated coronary artery disease as the driver of outcomes [<xref ref-type="bibr" rid="CR16">16</xref>]. Similarly, there is also evidence emerging for a causative role for type 1 diabetes leading to DCM, irrespective of obesity or hypertension status [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec3"><title>The Obesity Paradox</title><p id="Par11">The observation that patients with obesity (as measured by BMI) and HF (in particular with reduced LV systolic function) show better short to mid-term outcomes as compared to leaner patients is termed the obesity paradox [<xref ref-type="bibr" rid="CR23">23</xref>]. This effect is counter intuitive as obesity leads to adverse cardiac remodeling and reduced metabolic efficiency, in particular in dilated cardiomyopathy [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par12">A number of studies have questioned the presence of a paradox [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] in particular, given in earlier studies, BMI has been used as a measure of adiposity which has several limitations. BMI does not accurately capture the extent of visceral fat relative to muscle mass nor does it differentiate retained fluid in decompensated HF from flesh weight. Moreover, these studies have not incorporated exercise capacity or other measures of cardio-respiratory fitness. In an analysis of the PARADIGM-HF study (<italic>n</italic>&#x02009;=&#x02009;8,389), when waist to height ratio which is more likely to accurately capture central obesity, rather than BMI, was used to assess outcomes, no survival-paradox was observed [<xref ref-type="bibr" rid="CR28">28</xref>]. Similarly, in a paediatric population of patients with DCM (<italic>n</italic>&#x02009;=&#x02009;904, 13.3% obese), obesity did not confer a survival benefit [<xref ref-type="bibr" rid="CR27">27</xref>]. Earlier studies reporting the paradox were marred by confounders and collider bias. Mendelian randomisation studies suggest a causal relationship between obesity and heart failure [<xref ref-type="bibr" rid="CR29">29</xref>]. A growing body of evidence has convincingly demonstrated no survival benefit from obesity in HF when alternative anthropometric measures which more accurately capture the degree of adiposity are employed. Variation in adiposity measures are likely to account for the discrepancies in reported outcomes.</p></sec><sec id="Sec4"><title>Metabolic Syndrome, Metabolomics and DCM</title><p id="Par13">The failing heart is considered &#x02018;starved&#x02019; of energy. Typically, in heart failure there is increased glycolysis as a compensatory response to reduced mitochondrial oxidative capacity. In DCM associated with metabolic syndrome, there is a metabolic switch with an overreliance on free fatty acid (FFA) oxidation leading to reduced myocardial glucose uptake and oxidation [<xref ref-type="bibr" rid="CR30">30</xref>]. Although this is less efficient, the failing heart relies on FFAs to generate most of its energy. In an analysis of biopsies in end stage DCM patients, a paucity of intracardiac free fatty acids was observed suggesting a problem with FFA import impairing the failing heart in meeting its fuel demands [<xref ref-type="bibr" rid="CR31">31</xref>]. Other studies have not replicated these findings [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Balance between glucose and fatty acid oxidation may depend on drivers of heart failure. Obesity/metabolic syndrome with increased FFA availability may predispose the DCM heart to increase FFA oxidation. A distinct phenotype is seen with DCM resulting in inefficient oxidative metabolism, insulin resistance and inflammation [<xref ref-type="bibr" rid="CR34">34</xref>]. Further larger scale studies are required to untangle the complexities of energy metabolism in DCM.</p><p id="Par14">The use of metabolomic technologies has opened avenues of research in the discovery of biomarkers for the diagnosis, response to treatment and prognosis of DCM [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Even though common metabolomic perturbations are seen in heart failure of various etiologies, distinct profiles are observed in DCM as compared with heart failure as a result of other pathologies such as ischaemic (ICM) and valvular disease, with disease specific metabolomic signatures [<xref ref-type="bibr" rid="CR37">37</xref>]. In one recent study of 65 patients with acute and chronic heart failure (DCM&#x02009;=&#x02009;25); 630 plasma metabolites were analyzed. Metabolites of fatty acid metabolism were affected in both DCM and ICM compared with control, emphasizing general abnormalities of lipid metabolism and lipo-toxicity in patients with HF. However, of the total, 30 metabolites were altered in DCM as compared to controls and 8 metabolites (serine, lysophosphatidylcholine, cholesteryl esters [16:0, 18:1, 18:3, 20:3, 20:4, 22:5]) were altered when DCM was compared with ICM [<xref ref-type="bibr" rid="CR38">38</xref>]. In another study, (DCM&#x02009;=&#x02009;38, ICM&#x02009;=&#x02009;18, healthy controls&#x02009;=&#x02009;20) the metabolomic profile of plasma samples identified important dysregulated pathways. Alpha-linolenic acid metabolism was identified as a significant pathway in the DCM group whereas linoleic acid, D-Glutamine and D-glutamate metabolism were identified as significant pathways in the ICM group. The group also identified six metabolites (phosphatidylcholine 1-pyrroline-2-carboxylate, norvaline, lysophosphatidylinositol [16:0/0:0], phosphatidylglycerol [6:0/8:0], fatty acid esters of hydroxy fatty acid [24:1] and phosphatidylcholine [18:0/18:3] to be significantly different between patients with DCM and ICM [<xref ref-type="bibr" rid="CR37">37</xref>]. These data suggest disease specific metabolomic perturbation, challenging the notion of a universal HF metabolomic signature. Limitations include small numbers of patients, lack of generalizability to wider ancestries and the use of animal models and explanted hearts for tissue metabolomic analysis. Adequately powered studies with both plasma and tissue analysis need to be conducted to explore the clinical potential of disease specific metabolomic signatures in the diagnosis and management of DCM.</p></sec><sec id="Sec5"><title>Cardio-Renal Syndrome in DCM</title><p id="Par15">Cardio-renal syndrome encompasses a bidirectional pathology involving the heart and kidneys classified into several types based on which organ is felt to be the primary driver of dysfunction [<xref ref-type="bibr" rid="CR39">39</xref>]. Both organs are intricately linked as the kidneys are reliant on the heart for adequate perfusion and in turn dictate volume status and therefore myocardial volume load. Poor renal perfusion due to heart failure leads to activation of the renin-angiotensin-aldosterone and sympathetic systems which in turn can lead to fluid retention and vascular congestion exacerbating cardiac output leading to a vicious spiral [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par16">Many risk factors are shared by renal disease and heart failure and up to half of patients with heart failure have some degree of kidney failure [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. The reported incidence of chronic kidney disease in DCM varies ranging from 15 to 40% [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Renal impairment is associated with worse clinical outcomes in DCM. Impaired renal function also may restrict pharmacological treatment options. In a large Swedish registry of heart failure patients (<italic>n</italic>&#x02009;=&#x02009;47, 716), 17% of patients of at least moderate renal impairment (eGFR&#x02009;&#x0003c;&#x02009;60 mL/min/1.73&#x02005;m<sup>2</sup>) had DCM as the underlying heart failure etiology. Renal dysfunction was associated with mortality irrespective of age or presence of diabetes [<xref ref-type="bibr" rid="CR45">45</xref>]. In a study of 206 patients with DCM (mean follow-up 55.6&#x02009;&#x000b1;&#x02009;18.4months); renal impairment (GFR&#x02009;&#x0003c;&#x02009;60&#x000a0;ml/min/1.73m<sup>2</sup>) was again identified as an independent predictor of the composite end point of all-cause mortality or heart transplantation (HR 2.42, 95% CI: 1.36&#x02013;4.29; <italic>p</italic>&#x02009;=&#x02009;0.003) [<xref ref-type="bibr" rid="CR46">46</xref>].</p></sec><sec id="Sec6"><title>Impact of Concomitant Diabetes and CKD in DCM</title><p id="Par17">In a recent study of primary care records linked with hospital episode statistics across general practices in England, heart failure (all causes) was present in 13.7% of the population with CKD and T2DM (<italic>n</italic>&#x02009;=&#x02009;183,997). All-cause mortality (rate/1000-person years; 192.9, 95% CI: 188.8&#x02013;197.0) and cardiovascular outcomes (mortality/hospitalization; 149.0, 95% CI: 145.4&#x02013;152.7) were highest when all three were present. The study also reported low use of newer therapies in the cardio-renal-metabolic domain (Sodium-glucose co-transporter-2 (SGLT2) inhibitor use&#x02009;=&#x02009;2.8%; Glucagon-like peptide-1 (GLP-1) use&#x02009;=&#x02009;3.4%) although with a trend towards increasing use [<xref ref-type="bibr" rid="CR47">47</xref>]. Similar results were reported in another study analyzing new onset heart failure (<italic>n</italic>&#x02009;=&#x02009;87,709) using the same database. Patients with heart failure, CKD and T2DM constituted 16% of the population and the presence of CKD and T2DM in heart failure was associated with the worst median survival (ranging from 2. 8&#x02013;0.7 years based on CKD stage) [<xref ref-type="bibr" rid="CR8">8</xref>]. Whilst these and other studies report worse prognosis [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>], there is paucity of data on outcomes specific to dilated cardiomyopathy with co-existent diabetes and chronic kidney failure. In a recent Swedish national registry study (<italic>n</italic>&#x02009;=&#x02009;27,647, prevalence of HF-T2DM-CKD&#x02009;=&#x02009;13%), the etiology of heart failure was non-ischaemic in 49% of patients with HF, CKD and T2DM. All-cause mortality and MACE were highest when all three were present (HR for all-cause mortality; 3.22, 95% CI: 3.05&#x02013;3.39) [<xref ref-type="bibr" rid="CR50">50</xref>]. Larger studies are required to ascertain outcomes in DCM patients with multimorbidity to identify gaps in treatments in order to direct healthcare resources appropriately.</p></sec><sec id="Sec7"><title>Interaction Between Genetics, Sex and Cardio-Renal Metabolic Profile in DCM</title><p id="Par18">The genetic architecture in DCM is of prognostic significance. A familial cause is implicated in 25&#x02013;35% of cases and many pathological and likely pathological variants are associated with worse cardiovascular outcomes [<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>].&#x000a0;A study in 487 patients with DCM showed that carriers of desmosomal and lamin A/C (LMNA) genetic variants experienced a significantly higher rate of ventricular arrhythmias and sudden cardiac death (SCD), independent of ejection fraction [<xref ref-type="bibr" rid="CR54">54</xref>]. Similarly, carriers of titin-truncating variants, the most common genetic cause of DCM, in certain settings, appears to increase the risk of life-threatening arrhythmias [<xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par19">Interestingly, in a large study of 60,706 individuals, mutation in the LMNA gene (variant p.G602S) was shown to associate with type 2 diabetes [<xref ref-type="bibr" rid="CR56">56</xref>]. Other mutations in LMNA genes have also been shown to associate with severe metabolic syndrome [<xref ref-type="bibr" rid="CR57">57</xref>]. In one study, genes involved in lipid metabolism were able to predict the risk of DCM with good accuracy (AUC, training set 0.936; test set 0.737) [<xref ref-type="bibr" rid="CR58">58</xref>]. In another study, authors analyzed the Gene Expression Omnibus (GEO) dataset to identify differentially expressed genes in obesity and DCM and showed that genes implicated in oxidative stress, metabolic disorders and fibrosis play roles in obesity induced DCM [<xref ref-type="bibr" rid="CR59">59</xref>]. Further evidence linking obesity and DCM genetics was reported by Zheng et al. in a large genome wide association study. Authors developed a polygenic risk score for DCM risk in participants in the UK biobank (AUC 0.71) using common genetic variants (&#x0003e;&#x02009;500,000 single nucleotide polymorphisms). The risk score was shown to associate with obesity amongst other cardiovascular diseases on phenome-wide association studies suggesting a causal relationship [<xref ref-type="bibr" rid="CR60">60</xref>]. In totality, this body of evidence appears to suggest common genetic pathways between metabolic disease and DCM.</p><p id="Par20">Biological sex has also been shown to impact the clinical course and outcomes in DCM. There is a preponderance of male sex in DCM studies with a 3:1 ratio to female patients. This imbalance is not explained by survival bias and suggests greater penetrance or detection in men. A number of studies have reported worse cardiovascular outcomes and all-cause mortality with male sex in DCM [<xref ref-type="bibr" rid="CR61">61</xref>&#x02013;<xref ref-type="bibr" rid="CR65">65</xref>].&#x000a0;A meta-analysis of 5 studies (<italic>n</italic>&#x02009;=&#x02009;5,709) showed higher all-cause mortality (HR 1.61, 95% CI: 1.36&#x02013;1.90; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.00001), SCD (HR 1.80, 95% CI: 1.63&#x02013;2.61; <italic>p</italic>&#x02009;=&#x02009;0.002) and cardiovascular mortality (HR 1.67, 95% CI: 1.25&#x02013;2.23; <italic>p</italic>&#x02009;=&#x02009;0.0005) in male patients with DCM as compared to female [<xref ref-type="bibr" rid="CR64">64</xref>]. However, more recently this concept has been challenged. In a recent prospective study by our group (<italic>n</italic>&#x02009;=&#x02009;604, 206 female, median follow up 3.9 years), despite a more favourable profile (less myocardial fibrosis, higher LV ejection fraction), the composite of cardiovascular mortality or major heart failure events was higher in female patients with DCM as compared to those of males with DCM (8.6% vs. 4.4%, adjusted HR 3.14, 95% CI: 1.55&#x02013;6.35; <italic>p</italic>&#x02009;=&#x02009;0.001) at two years suggesting worse prognosis in female patients early on in the disease trajectory despite a milder phenotype [<xref ref-type="bibr" rid="CR66">66</xref>]. Further large scale studies are required to shed additional light on the role that biological sex plays in determining both short and longer-term outcomes in patients with DCM.</p></sec><sec id="Sec8"><title>Novel Therapeutic Directions</title><p id="Par21">There is a need to develop therapies targeting the common pathophysiological pathways of DCM and metabolic-renal dysfunction. Trimetazidine (an inhibitor of long-chain 3-ketoacyl-CoA thiolase) inhibits oxidation of free fatty acids thereby shifting substrate utilization to glucose and improving cardiac metabolism. In a recent meta-analysis of 28 studies (<italic>n</italic>&#x02009;=&#x02009;2552, median follow up 6 months) of patients with HF with reduced ejection fraction (non-ischaemic, <italic>n</italic>&#x02009;=&#x02009;359), Trimetazidine was associated with significantly reduced cardiovascular mortality (Odds ratio; OR 0.33, 95% CI: 0.21 to 0.53) and HF hospitalizations (OR 0.42, 95% CI: 0.29 to 0.60) [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par22">With the advent of SGLT2 inhibitors, intervention on a number of pathways, both related to diabetes and more likely common pro-inflammatory and pro-fibrotic pathways, has already impacted significantly on improving outcomes for patients with heart failure and DCM. Developed initially as glucose lowering agents in type 2 diabetes, a number of trials have shown beneficial effects of these agents in HF and CKD irrespective of diabetes status [<xref ref-type="bibr" rid="CR68">68</xref>&#x02013;<xref ref-type="bibr" rid="CR71">71</xref>] The exact mechanisms by which they exert their effects in HF are unknown. Modulating key cellular mechanisms affecting inflammation is proposed as a key hypothesis. In one small observational study of patients with DCM (<italic>n</italic>&#x02009;=&#x02009;50), Dapagliflozin use was associated with better cardiac function at 12 months as compared with conventional therapy without SGLT2 inhibitor use [<xref ref-type="bibr" rid="CR70">70</xref>]. Similarly, the GLP-1 agonist, Semaglutide has recently been shown to improve outcomes in patients with HF of both preserved and reduced ejection fraction and obesity (irrespective of diabetes status) in the large randomized controlled SELECT trial [<xref ref-type="bibr" rid="CR72">72</xref>]. Whether GLP1-agonists will also become a significant pillar of treatment in the management of DCM and HF with reduced ejection fraction in general remains to be determined [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>].</p></sec></sec><sec id="Sec9"><title>Conclusions</title><p id="Par23">Advances in the diagnosis and management of dilated cardiomyopathy have resulted in improvement in outcomes over the last two decades. However, an ageing population accumulating metabolic and renal comorbidities in DCM pose new challenges. The cardio-renal-metabolic profile is an important consideration in all patients with DCM and optimization should become a benchmark component of clinical care. Large scale studies are required to ascertain the role of biological sex, genetics and ancestry to fill gaps in knowledge in order that equitable health care is provided universally.</p></sec><sec id="Sec119"><title>Key References</title><p id="Par24">
<list list-type="bullet"><list-item><p id="Par25">Ndumele CE, Neeland IJ, Tuttle KR, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement from the American Heart Association. Circulation. 2023;148:e183-e201.</p></list-item><list-item><p id="Par26">
<list list-type="bullet"><list-item><p id="Par27">This scientific statement from the American Heart Association summarizes the key considerations in the management of cardiovascular-kidney-metabolic syndrome in established cardiovascular disease.</p></list-item></list>
</p></list-item><list-item><p id="Par28">Eda Y, Nabeta T, Iikura S, et al. Non-dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes. ESC Heart Fail. 2024;11:236&#x02013;245.</p></list-item><list-item><p id="Par29">
<list list-type="bullet"><list-item><p id="Par30">This recent study following up patient with dilated cardiomyopathy reported metabolic risk factors to be commonly present in these patients.</p></list-item></list>
</p></list-item><list-item><p id="Par31">&#x000d6;sterman J, Al-Sodany E, Haugen L&#x000f6;fman I, Barany P, Evans M. Heart failure: the grim reaper of the cardio&#x02010;renal&#x02010;metabolic triad. ESC Heart Fail. 2024;11:2334&#x02013;2343.</p></list-item><list-item><p id="Par32">
<list list-type="bullet"><list-item><p id="Par33">In this study following up patients for up to 10 years, the concomitant presence of chronic kidney disease, diabetes and heart failure portended the worst prognostic outcomes.</p></list-item></list>
</p></list-item></list>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contributions</title><p>TA performed literature review and critical analysis, wrote the manuscript and designed the infographic. DJH and BPH provided expert opinion, key literature analysis and revised the manuscript. CYM revised the manuscript. SKP conceived the manuscript outline, revised the manuscript and provided expert opinion and supervision throughout.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Dr. Brian Halliday is supported by an Intermediate Clinical Research Fellowship from the British Heart Foundation (FS/ICRF/21/26019) and Rosetrees Trust.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Human and Animal Rights and Informed Consent</title><p id="Par34">This study is a critical appraisal and review of the published literature. No ethical approval was required. This article does not contain any new studies with human or animal subjects performed by any of the authors.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing Interests</title><p id="Par35">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>SL</given-names></name><name><surname>Abate</surname><given-names>D</given-names></name><name><surname>Abate</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Global, regional, and National incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990&#x02013;2017: a systematic analysis for the global burden of disease study 2017</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>1789</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32279-7</pub-id><pub-id pub-id-type="pmid">30496104</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">James SL, Abate D, Abate KH, et al. Global, regional, and National incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990&#x02013;2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789&#x02013;858.<pub-id pub-id-type="pmid">30496104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Savarese</surname><given-names>G</given-names></name><name><surname>Becher</surname><given-names>PM</given-names></name><name><surname>Lund</surname><given-names>LH</given-names></name><name><surname>Seferovic</surname><given-names>P</given-names></name><name><surname>Rosano</surname><given-names>GMC</given-names></name><name><surname>Coats</surname><given-names>AJS</given-names></name></person-group><article-title>Global burden of heart failure: a comprehensive and updated review of epidemiology</article-title><source>Cardiovasc Res</source><year>2023</year><volume>118</volume><fpage>3272</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvac013</pub-id><pub-id pub-id-type="pmid">35150240</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118:3272&#x02013;87.<pub-id pub-id-type="pmid">35150240</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>McNally</surname><given-names>EM</given-names></name><name><surname>Mestroni</surname><given-names>L</given-names></name></person-group><article-title>Dilated cardiomyopathy</article-title><source>Circ Res</source><year>2017</year><volume>121</volume><fpage>731</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309396</pub-id><pub-id pub-id-type="pmid">28912180</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">McNally EM, Mestroni L. Dilated cardiomyopathy. Circ Res. 2017;121:731&#x02013;48.<pub-id pub-id-type="pmid">28912180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Hershberger</surname><given-names>RE</given-names></name><name><surname>Hedges</surname><given-names>DJ</given-names></name><name><surname>Morales</surname><given-names>A</given-names></name></person-group><article-title>Dilated cardiomyopathy: the complexity of a diverse genetic architecture</article-title><source>Nat Rev Cardiol</source><year>2013</year><volume>10</volume><fpage>531</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2013.105</pub-id><pub-id pub-id-type="pmid">23900355</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531&#x02013;47.<pub-id pub-id-type="pmid">23900355</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="book"><person-group person-group-type="author"><name><surname>Merlo</surname><given-names>M</given-names></name><name><surname>Stolfo</surname><given-names>D</given-names></name><name><surname>Caiffa</surname><given-names>T</given-names></name><name><surname>Pivetta</surname><given-names>A</given-names></name><name><surname>Sinagra</surname><given-names>G</given-names></name></person-group><article-title>Clinical presentation, spectrum of disease, and natural history</article-title><source>Dilated cardiomyopathy</source><year>2019</year><publisher-loc>Cham</publisher-loc><publisher-name>Springer International Publishing</publisher-name><fpage>71</fpage><lpage>82</lpage></element-citation><mixed-citation id="mc-CR5" publication-type="book">Merlo M, Stolfo D, Caiffa T, Pivetta A, Sinagra G. Clinical presentation, spectrum of disease, and natural history. Dilated cardiomyopathy. Cham: Springer International Publishing; 2019. pp. 71&#x02013;82.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Merlo</surname><given-names>M</given-names></name><name><surname>Cannat&#x000e0;</surname><given-names>A</given-names></name><name><surname>Pio Loco</surname><given-names>C</given-names></name><etal/></person-group><article-title>Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy</article-title><source>Eur J Heart Fail</source><year>2020</year><volume>22</volume><fpage>1111</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/ejhf.1914</pub-id><pub-id pub-id-type="pmid">32452075</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Merlo M, Cannat&#x000e0; A, Pio Loco C, et al. Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail. 2020;22:1111&#x02013;21.<pub-id pub-id-type="pmid">32452075</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Ndumele</surname><given-names>CE</given-names></name><name><surname>Neeland</surname><given-names>IJ</given-names></name><name><surname>Tuttle</surname><given-names>KR</given-names></name><etal/></person-group><article-title>A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: A scientific statement from the American heart association</article-title><source>Circulation</source><year>2023</year><volume>148</volume><fpage>1636</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000001186</pub-id><pub-id pub-id-type="pmid">37807920</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: A scientific statement from the American heart association. Circulation. 2023;148:1636&#x02013;64.<pub-id pub-id-type="pmid">37807920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>CA</given-names></name><name><surname>Seidu</surname><given-names>S</given-names></name><name><surname>Zaccardi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over Twenty years</article-title><source>EClinicalMedicine</source><year>2021</year><volume>32</volume><fpage>100739</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.100739</pub-id><pub-id pub-id-type="pmid">33688855</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Lawson CA, Seidu S, Zaccardi F, et al. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over Twenty years. EClinicalMedicine. 2021;32:100739.<pub-id pub-id-type="pmid">33688855</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Savarese</surname><given-names>G</given-names></name><name><surname>Settergren</surname><given-names>C</given-names></name><name><surname>Schrage</surname><given-names>B</given-names></name><etal/></person-group><article-title>Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design</article-title><source>Int J Cardiol</source><year>2020</year><volume>313</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2020.04.068</pub-id><pub-id pub-id-type="pmid">32360702</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Savarese G, Settergren C, Schrage B, et al. Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. Int J Cardiol. 2020;313:76&#x02013;82.<pub-id pub-id-type="pmid">32360702</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Chioncel</surname><given-names>O</given-names></name><name><surname>Lainscak</surname><given-names>M</given-names></name><name><surname>Seferovic</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid&#x02010;range and reduced ejection fraction: an analysis of the ESC heart failure Long&#x02010;Term registry</article-title><source>Eur J Heart Fail</source><year>2017</year><volume>19</volume><fpage>1574</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1002/ejhf.813</pub-id><pub-id pub-id-type="pmid">28386917</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid&#x02010;range and reduced ejection fraction: an analysis of the ESC heart failure Long&#x02010;Term registry. Eur J Heart Fail. 2017;19:1574&#x02013;85.<pub-id pub-id-type="pmid">28386917</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>GA</given-names></name><name><surname>Amitay</surname><given-names>EL</given-names></name><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Steubl</surname><given-names>D</given-names></name></person-group><article-title>The bidirectional association of chronic kidney disease, type 2 diabetes, atherosclerotic cardiovascular disease, and heart failure: the Cardio&#x02013;Renal&#x02013;Metabolic syndrome</article-title><source>Metab Syndr Relat Disord</source><year>2023</year><volume>21</volume><fpage>261</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1089/met.2023.0006</pub-id><pub-id pub-id-type="pmid">37130317</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Nichols GA, Amitay EL, Chatterjee S, Steubl D. The bidirectional association of chronic kidney disease, type 2 diabetes, atherosclerotic cardiovascular disease, and heart failure: the Cardio&#x02013;Renal&#x02013;Metabolic syndrome. Metab Syndr Relat Disord. 2023;21:261&#x02013;6.<pub-id pub-id-type="pmid">37130317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Diabetes, heart failure, and renal dysfunction: the vicious circles</article-title><source>Prog Cardiovasc Dis</source><year>2019</year><volume>62</volume><fpage>298</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2019.07.003</pub-id><pub-id pub-id-type="pmid">31377223</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Prog Cardiovasc Dis. 2019;62:298&#x02013;302.<pub-id pub-id-type="pmid">31377223</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Eda</surname><given-names>Y</given-names></name><name><surname>Nabeta</surname><given-names>T</given-names></name><name><surname>Iikura</surname><given-names>S</given-names></name><etal/></person-group><article-title>Non-dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes</article-title><source>ESC Heart Fail</source><year>2024</year><volume>11</volume><fpage>1463</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14711</pub-id><pub-id pub-id-type="pmid">38320776</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Eda Y, Nabeta T, Iikura S, et al. Non-dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes. ESC Heart Fail. 2024;11:1463&#x02013;71.<pub-id pub-id-type="pmid">38320776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Dziewi&#x00119;cka</surname><given-names>E</given-names></name><name><surname>Winiarczyk</surname><given-names>M</given-names></name><name><surname>Wi&#x0015b;niowska-&#x0015a;mia&#x00142;ek</surname><given-names>S</given-names></name><etal/></person-group><article-title>Comparison of clinical course and outcomes between dilated and hypokinetic Non-Dilated cardiomyopathy</article-title><source>Cardiology</source><year>2023</year><volume>148</volume><fpage>395</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1159/000531534</pub-id><pub-id pub-id-type="pmid">37311443</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Dziewi&#x00119;cka E, Winiarczyk M, Wi&#x0015b;niowska-&#x0015a;mia&#x00142;ek S, et al. Comparison of clinical course and outcomes between dilated and hypokinetic Non-Dilated cardiomyopathy. Cardiology. 2023;148:395&#x02013;401.<pub-id pub-id-type="pmid">37311443</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>J</given-names></name><name><surname>Schaufelberger</surname><given-names>M</given-names></name><name><surname>Lindgren</surname><given-names>M</given-names></name><etal/></person-group><article-title>Higher body mass index in adolescence predicts cardiomyopathy risk in midlife</article-title><source>Circulation</source><year>2019</year><volume>140</volume><fpage>117</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.039132</pub-id><pub-id pub-id-type="pmid">31132859</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Robertson J, Schaufelberger M, Lindgren M, et al. Higher body mass index in adolescence predicts cardiomyopathy risk in midlife. Circulation. 2019;140:117&#x02013;25.<pub-id pub-id-type="pmid">31132859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Marwick</surname><given-names>TH</given-names></name><name><surname>Ritchie</surname><given-names>R</given-names></name><name><surname>Shaw</surname><given-names>JE</given-names></name><name><surname>Kaye</surname><given-names>D</given-names></name></person-group><article-title>Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>2018</year><volume>71</volume><fpage>339</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.11.019</pub-id><pub-id pub-id-type="pmid">29348027</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71:339&#x02013;51.<pub-id pub-id-type="pmid">29348027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Rosano</surname><given-names>GM</given-names></name><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Seferovic</surname><given-names>P</given-names></name></person-group><article-title>Heart failure in patients with diabetes mellitus</article-title><source>Card Fail Rev</source><year>2017</year><volume>03</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.15420/cfr.2016:20:2</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. Card Fail Rev. 2017;03:52.</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Tatsumi</surname><given-names>K</given-names></name><name><surname>Matsuzoe</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name></person-group><article-title>Impact of diabetes mellitus on left ventricular longitudinal function of patients with non-ischemic dilated cardiomyopathy</article-title><source>Cardiovasc Diabetol</source><year>2020</year><volume>19</volume><fpage>84</fpage><pub-id pub-id-type="doi">10.1186/s12933-020-01063-y</pub-id><pub-id pub-id-type="pmid">32534593</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Tanaka H, Tatsumi K, Matsuzoe H, Matsumoto K, Hirata K. Impact of diabetes mellitus on left ventricular longitudinal function of patients with non-ischemic dilated cardiomyopathy. Cardiovasc Diabetol. 2020;19:84.<pub-id pub-id-type="pmid">32534593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>MR</given-names></name><name><surname>Petrie</surname><given-names>MC</given-names></name><name><surname>Varyani</surname><given-names>F</given-names></name><etal/></person-group><article-title>Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme</article-title><source>Eur Heart J</source><year>2008</year><volume>29</volume><fpage>1377</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehn153</pub-id><pub-id pub-id-type="pmid">18413309</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377&#x02013;85.<pub-id pub-id-type="pmid">18413309</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Silverdal</surname><given-names>J</given-names></name><name><surname>Sj&#x000f6;land</surname><given-names>H</given-names></name><name><surname>Pivodic</surname><given-names>A</given-names></name><name><surname>Dahlstr&#x000f6;m</surname><given-names>U</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Bollano</surname><given-names>E</given-names></name></person-group><article-title>Prognostic differences in long-standing vs. recent&#x02010;onset dilated cardiomyopathy</article-title><source>ESC Heart Fail</source><year>2022</year><volume>9</volume><fpage>1294</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13816</pub-id><pub-id pub-id-type="pmid">35132793</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Silverdal J, Sj&#x000f6;land H, Pivodic A, Dahlstr&#x000f6;m U, Fu M, Bollano E. Prognostic differences in long-standing vs. recent&#x02010;onset dilated cardiomyopathy. ESC Heart Fail. 2022;9:1294&#x02013;303.<pub-id pub-id-type="pmid">35132793</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Meindl</surname><given-names>C</given-names></name><name><surname>Hochadel</surname><given-names>M</given-names></name><name><surname>Frankenstein</surname><given-names>L</given-names></name><etal/></person-group><article-title>The role of diabetes in cardiomyopathies of different etiologies&#x02014;Characteristics and 1-year follow-up results of the EVITA-HF registry Den Uil C, editor</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><fpage>e0234260</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0234260</pub-id><pub-id pub-id-type="pmid">32525964</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Meindl C, Hochadel M, Frankenstein L, et al. The role of diabetes in cardiomyopathies of different etiologies&#x02014;Characteristics and 1-year follow-up results of the EVITA-HF registry Den Uil C, editor. PLoS ONE. 2020;15:e0234260.<pub-id pub-id-type="pmid">32525964</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Quan</surname><given-names>E</given-names></name><name><surname>Zeng</surname><given-names>T</given-names></name><etal/></person-group><article-title>Type 1 diabetes, its complications, and non-ischemic cardiomyopathy: a Mendelian randomization study of European ancestry</article-title><source>Cardiovasc Diabetol</source><year>2024</year><volume>23</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/s12933-023-02117-7</pub-id><pub-id pub-id-type="pmid">38218861</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Zhao Y, Quan E, Zeng T, et al. Type 1 diabetes, its complications, and non-ischemic cardiomyopathy: a Mendelian randomization study of European ancestry. Cardiovasc Diabetol. 2024;23:31.<pub-id pub-id-type="pmid">38218861</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Alebna</surname><given-names>PL</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Yehya</surname><given-names>A</given-names></name><name><surname>daSilva-deAbreu</surname><given-names>A</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>Carbone</surname><given-names>S</given-names></name></person-group><article-title>Update on obesity, the obesity paradox, and obesity management in heart failure</article-title><source>Prog Cardiovasc Dis</source><year>2024</year><volume>82</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2024.01.003</pub-id><pub-id pub-id-type="pmid">38199320</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Alebna PL, Mehta A, Yehya A, daSilva-deAbreu A, Lavie CJ, Carbone S. Update on obesity, the obesity paradox, and obesity management in heart failure. Prog Cardiovasc Dis. 2024;82:34&#x02013;42.<pub-id pub-id-type="pmid">38199320</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Rayner</surname><given-names>JJ</given-names></name><name><surname>Abdesselam</surname><given-names>I</given-names></name><name><surname>d&#x02019;Arcy</surname><given-names>J</given-names></name><etal/></person-group><article-title>Obesity-related ventricular remodelling is exacerbated in dilated and hypertrophic cardiomyopathy</article-title><source>Cardiovasc Diagn Ther</source><year>2020</year><volume>10</volume><fpage>559</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.21037/cdt-19-587</pub-id><pub-id pub-id-type="pmid">32695637</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Rayner JJ, Abdesselam I, d&#x02019;Arcy J, et al. Obesity-related ventricular remodelling is exacerbated in dilated and hypertrophic cardiomyopathy. Cardiovasc Diagn Ther. 2020;10:559&#x02013;67.<pub-id pub-id-type="pmid">32695637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Rayner JJ, Peterzan MA, Clarke WT, Rodgers CT, Neubauer S, Rider OJ. Obesity modifies the energetic phenotype of dilated cardiomyopathy. Eur Heart J. 2021;43.</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Obesity paradox in heart failure revisited: etiology as effect modifier</article-title><source>Am J Cardiol</source><year>2023</year><volume>207</volume><fpage>294</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2023.09.024</pub-id><pub-id pub-id-type="pmid">37769574</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Huang L, Zhao X, Liang L, et al. Obesity paradox in heart failure revisited: etiology as effect modifier. Am J Cardiol. 2023;207:294&#x02013;301.<pub-id pub-id-type="pmid">37769574</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Castleberry</surname><given-names>CD</given-names></name><name><surname>Jefferies</surname><given-names>JL</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><etal/></person-group><article-title>No obesity paradox in pediatric patients with dilated cardiomyopathy</article-title><source>JACC Heart Fail</source><year>2018</year><volume>6</volume><fpage>222</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.jchf.2017.11.015</pub-id><pub-id pub-id-type="pmid">29428438</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Castleberry CD, Jefferies JL, Shi L, et al. No obesity paradox in pediatric patients with dilated cardiomyopathy. JACC Heart Fail. 2018;6:222&#x02013;30.<pub-id pub-id-type="pmid">29428438</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>JH</given-names></name><name><surname>Petrie</surname><given-names>MC</given-names></name><name><surname>Jhund</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox</article-title><source>Eur Heart J</source><year>2023</year><volume>44</volume><fpage>1136</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad083</pub-id><pub-id pub-id-type="pmid">36944496</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Butt JH, Petrie MC, Jhund PS, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J. 2023;44:1136&#x02013;53.<pub-id pub-id-type="pmid">36944496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Lumbers RT, Katsoulis M, Henry A et al. Body mass index and heart failure risk: a cohort study in 1.5 million individuals and Mendelian randomisation analysis. medRxiv 2020092320200360. 2020.</mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Lopaschuk</surname><given-names>GD</given-names></name><name><surname>Karwi</surname><given-names>QG</given-names></name><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Wende</surname><given-names>AR</given-names></name><name><surname>Abel</surname><given-names>ED</given-names></name></person-group><article-title>Cardiac energy metabolism in heart failure</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><fpage>1487</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.318241</pub-id><pub-id pub-id-type="pmid">33983836</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021;128:1487&#x02013;513.<pub-id pub-id-type="pmid">33983836</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Flam E, Jang C, Murashige D et al. Integrated landscape of cardiac metabolism in end-stage human nonischemic dilated cardiomyopathy. Nat Cardiovasc Res. 2022;1.</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Funada</surname><given-names>J</given-names></name><name><surname>Betts</surname><given-names>TR</given-names></name><name><surname>Hodson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Substrate utilization by the failing human heart by direct quantification using Arterio-Venous blood sampling Brandstaetter A, editor</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><fpage>e7533</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0007533</pub-id><pub-id pub-id-type="pmid">19844574</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Funada J, Betts TR, Hodson L, et al. Substrate utilization by the failing human heart by direct quantification using Arterio-Venous blood sampling Brandstaetter A, editor. PLoS ONE. 2009;4:e7533.<pub-id pub-id-type="pmid">19844574</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>WD</given-names></name><name><surname>Green</surname><given-names>PG</given-names></name><name><surname>Lewis</surname><given-names>AJM</given-names></name><etal/></person-group><source>Retain Metabolic Flex Fail Hum Heart Circulation</source><year>2023</year><volume>148</volume><fpage>109</fpage><lpage>23</lpage></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Watson WD, Green PG, Lewis AJM, et al. Retain Metabolic Flex Fail Hum Heart Circulation. 2023;148:109&#x02013;23.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>TS</given-names></name><name><surname>Jansen</surname><given-names>KM</given-names></name></person-group><article-title>Impact of Obesity-Related inflammation on cardiac metabolism and function</article-title><source>J Lipid Atheroscler</source><year>2021</year><volume>10</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.12997/jla.2021.10.1.8</pub-id><pub-id pub-id-type="pmid">33537250</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Larsen TS, Jansen KM. Impact of Obesity-Related inflammation on cardiac metabolism and function. J Lipid Atheroscler. 2021;10:8.<pub-id pub-id-type="pmid">33537250</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Spoladore</surname><given-names>R</given-names></name><name><surname>Pinto</surname><given-names>G</given-names></name><name><surname>Daus</surname><given-names>F</given-names></name><name><surname>Pezzini</surname><given-names>S</given-names></name><name><surname>Kolios</surname><given-names>D</given-names></name><name><surname>Fragasso</surname><given-names>G</given-names></name></person-group><article-title>Metabolic approaches for the treatment of dilated cardiomyopathy</article-title><source>J Cardiovasc Dev Dis</source><year>2023</year><volume>10</volume><fpage>287</fpage><pub-id pub-id-type="pmid">37504543</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Spoladore R, Pinto G, Daus F, Pezzini S, Kolios D, Fragasso G. Metabolic approaches for the treatment of dilated cardiomyopathy. J Cardiovasc Dev Dis. 2023;10:287.<pub-id pub-id-type="pmid">37504543</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Ampong</surname><given-names>I</given-names></name></person-group><article-title>Metabolic and metabolomics insights into dilated cardiomyopathy</article-title><source>Ann Nutr Metab</source><year>2022</year><volume>78</volume><fpage>147</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1159/000524722</pub-id><pub-id pub-id-type="pmid">35472668</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Ampong I. Metabolic and metabolomics insights into dilated cardiomyopathy. Ann Nutr Metab. 2022;78:147&#x02013;55.<pub-id pub-id-type="pmid">35472668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Zhao J, Yang S, Jing R et al. Plasma metabolomic profiles differentiate patients with dilated cardiomyopathy and ischemic cardiomyopathy. Front Cardiovasc Med. 2020;7.</mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Kretzschmar T, Westphal J, Neugebauer S et al. Metabolic profiling identifies 1-MetHis and 3-IPA as potential diagnostic biomarkers for patients with acute and chronic heart failure with reduced ejection fraction. Circ Heart Fail. 2024;17.</mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Junho</surname><given-names>CVC</given-names></name><name><surname>Frisch</surname><given-names>J</given-names></name><name><surname>Soppert</surname><given-names>J</given-names></name><name><surname>Wollenhaupt</surname><given-names>J</given-names></name><name><surname>Noels</surname><given-names>H</given-names></name></person-group><article-title>Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in Understanding pathophysiology</article-title><source>Clin Kidney J</source><year>2023</year><volume>16</volume><fpage>1786</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1093/ckj/sfad085</pub-id><pub-id pub-id-type="pmid">37915935</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Junho CVC, Frisch J, Soppert J, Wollenhaupt J, Noels H. Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in Understanding pathophysiology. Clin Kidney J. 2023;16:1786&#x02013;803.<pub-id pub-id-type="pmid">37915935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Costanzo</surname><given-names>MR</given-names></name></person-group><article-title>The cardiorenal syndrome in heart failure</article-title><source>Cardiol Clin</source><year>2022</year><volume>40</volume><fpage>219</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ccl.2021.12.010</pub-id><pub-id pub-id-type="pmid">35465896</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Costanzo MR. The cardiorenal syndrome in heart failure. Cardiol Clin. 2022;40:219&#x02013;35.<pub-id pub-id-type="pmid">35465896</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Gerhardt</surname><given-names>LMS</given-names></name><name><surname>Kordsmeyer</surname><given-names>M</given-names></name><name><surname>Sehner</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages</article-title><source>Clin Res Cardiol</source><year>2023</year><volume>112</volume><fpage>868</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1007/s00392-022-02027-w</pub-id><pub-id pub-id-type="pmid">35648270</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Gerhardt LMS, Kordsmeyer M, Sehner S, et al. Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages. Clin Res Cardiol. 2023;112:868&#x02013;79.<pub-id pub-id-type="pmid">35648270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Schefold</surname><given-names>JC</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Hasenfuss</surname><given-names>G</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>von Haehling</surname><given-names>S</given-names></name></person-group><article-title>Heart failure and kidney dysfunction: epidemiology, mechanisms and management</article-title><source>Nat Rev Nephrol</source><year>2016</year><volume>12</volume><fpage>610</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2016.113</pub-id><pub-id pub-id-type="pmid">27573728</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12:610&#x02013;23.<pub-id pub-id-type="pmid">27573728</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Inciardi</surname><given-names>RM</given-names></name><name><surname>Merlo</surname><given-names>M</given-names></name><name><surname>Bellicini</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hepatic T1-time, cardiac structure and function and cardiovascular outcomes in patients with dilated cardiomyopathy</article-title><source>Eur J Intern Med</source><year>2024</year><volume>127</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.ejim.2024.04.009</pub-id><pub-id pub-id-type="pmid">38719725</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Inciardi RM, Merlo M, Bellicini M, et al. Hepatic T1-time, cardiac structure and function and cardiovascular outcomes in patients with dilated cardiomyopathy. Eur J Intern Med. 2024;127:84&#x02013;90.<pub-id pub-id-type="pmid">38719725</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Ababio</surname><given-names>Y</given-names></name><name><surname>Kelly</surname><given-names>SP</given-names></name><name><surname>Angeli</surname><given-names>FS</given-names></name><etal/></person-group><article-title>Prevalence and clinical burden of idiopathic dilated cardiomyopathy in the united States</article-title><source>Am J Med Open</source><year>2023</year><volume>10</volume><fpage>100038</fpage><pub-id pub-id-type="doi">10.1016/j.ajmo.2023.100038</pub-id><pub-id pub-id-type="pmid">39035243</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Ababio Y, Kelly SP, Angeli FS, et al. Prevalence and clinical burden of idiopathic dilated cardiomyopathy in the united States. Am J Med Open. 2023;10:100038.<pub-id pub-id-type="pmid">39035243</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f6;fman</surname><given-names>I</given-names></name><name><surname>Szummer</surname><given-names>K</given-names></name><name><surname>Hagerman</surname><given-names>I</given-names></name><name><surname>Dahlstr&#x000f6;m</surname><given-names>U</given-names></name><name><surname>Lund</surname><given-names>LH</given-names></name><name><surname>Jernberg</surname><given-names>T</given-names></name></person-group><article-title>Prevalence and prognostic impact of kidney disease on heart failure patients</article-title><source>Open Heart</source><year>2016</year><volume>3</volume><fpage>e000324</fpage><pub-id pub-id-type="doi">10.1136/openhrt-2015-000324</pub-id><pub-id pub-id-type="pmid">26848393</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">L&#x000f6;fman I, Szummer K, Hagerman I, Dahlstr&#x000f6;m U, Lund LH, Jernberg T. Prevalence and prognostic impact of kidney disease on heart failure patients. Open Heart. 2016;3:e000324.<pub-id pub-id-type="pmid">26848393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Karatolios</surname><given-names>K</given-names></name><name><surname>Holzendorf</surname><given-names>V</given-names></name><name><surname>Richter</surname><given-names>A</given-names></name><name><surname>Schieffer</surname><given-names>B</given-names></name><name><surname>Pankuweit</surname><given-names>S</given-names></name></person-group><article-title>Long-term outcome and predictors of outcome in patients with non-ischemic dilated cardiomyopathy</article-title><source>Int J Cardiol</source><year>2016</year><volume>220</volume><fpage>608</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.06.167</pub-id><pub-id pub-id-type="pmid">27390998</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Karatolios K, Holzendorf V, Richter A, Schieffer B, Pankuweit S. Long-term outcome and predictors of outcome in patients with non-ischemic dilated cardiomyopathy. Int J Cardiol. 2016;220:608&#x02013;12.<pub-id pub-id-type="pmid">27390998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>S</given-names></name><name><surname>Schmedt</surname><given-names>N</given-names></name><name><surname>Broughton</surname><given-names>J</given-names></name><name><surname>Kalra</surname><given-names>PA</given-names></name><name><surname>Tomlinson</surname><given-names>LA</given-names></name><name><surname>Quint</surname><given-names>JK</given-names></name></person-group><article-title>Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the clinical practice research datalink</article-title><source>BMJ Open</source><year>2023</year><volume>13</volume><fpage>e065927</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2022-065927</pub-id><pub-id pub-id-type="pmid">36882249</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Cook S, Schmedt N, Broughton J, Kalra PA, Tomlinson LA, Quint JK. Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the clinical practice research datalink. BMJ Open. 2023;13:e065927.<pub-id pub-id-type="pmid">36882249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Birkeland</surname><given-names>KI</given-names></name><name><surname>Bodegard</surname><given-names>J</given-names></name><name><surname>Eriksson</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study</article-title><source>Diabetes Obes Metab</source><year>2020</year><volume>22</volume><fpage>1607</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1111/dom.14074</pub-id><pub-id pub-id-type="pmid">32363737</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Birkeland KI, Bodegard J, Eriksson JW, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes Obes Metab. 2020;22:1607&#x02013;18.<pub-id pub-id-type="pmid">32363737</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>P</given-names></name><name><surname>Saxena</surname><given-names>N</given-names></name><name><surname>You</surname><given-names>AX</given-names></name><etal/></person-group><article-title>Effect of Multimorbidity on survival of patients diagnosed with heart failure: a retrospective cohort study in Singapore</article-title><source>BMJ Open</source><year>2018</year><volume>8</volume><fpage>e021291</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2017-021291</pub-id><pub-id pub-id-type="pmid">29780030</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Kaur P, Saxena N, You AX, et al. Effect of Multimorbidity on survival of patients diagnosed with heart failure: a retrospective cohort study in Singapore. BMJ Open. 2018;8:e021291.<pub-id pub-id-type="pmid">29780030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;sterman</surname><given-names>J</given-names></name><name><surname>Al-Sodany</surname><given-names>E</given-names></name><name><surname>Haugen L&#x000f6;fman</surname><given-names>I</given-names></name><name><surname>Barany</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>M</given-names></name></person-group><article-title>Heart failure: the Grim reaper of the cardio&#x02010;renal&#x02010;metabolic triad</article-title><source>ESC Heart Fail</source><year>2024</year><volume>11</volume><fpage>2334</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14810</pub-id><pub-id pub-id-type="pmid">38659273</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">&#x000d6;sterman J, Al-Sodany E, Haugen L&#x000f6;fman I, Barany P, Evans M. Heart failure: the Grim reaper of the cardio&#x02010;renal&#x02010;metabolic triad. ESC Heart Fail. 2024;11:2334&#x02013;43.<pub-id pub-id-type="pmid">38659273</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Sweet</surname><given-names>ME</given-names></name><name><surname>Taylor</surname><given-names>MR</given-names></name><name><surname>Mestroni</surname><given-names>L</given-names></name></person-group><article-title>Diagnosis, prevalence, and screening of Familial dilated cardiomyopathy</article-title><source>Expert Opin Orphan Drugs</source><year>2015</year><volume>3</volume><fpage>869</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1517/21678707.2015.1057498</pub-id><pub-id pub-id-type="pmid">27547593</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Sweet ME, Taylor MR, Mestroni L. Diagnosis, prevalence, and screening of Familial dilated cardiomyopathy. Expert Opin Orphan Drugs. 2015;3:869&#x02013;76.<pub-id pub-id-type="pmid">27547593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Escobar-Lopez</surname><given-names>L</given-names></name><name><surname>Ochoa</surname><given-names>JP</given-names></name><name><surname>Mirelis</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>2021</year><volume>78</volume><fpage>1682</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.08.039</pub-id><pub-id pub-id-type="pmid">34674813</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Escobar-Lopez L, Ochoa JP, Mirelis JG, et al. Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2021;78:1682&#x02013;99.<pub-id pub-id-type="pmid">34674813</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>E</given-names></name><name><surname>Peterson</surname><given-names>L</given-names></name><name><surname>Ai</surname><given-names>T</given-names></name><etal/></person-group><article-title>Evidence-Based assessment of genes in dilated cardiomyopathy</article-title><source>Circulation</source><year>2021</year><volume>144</volume><fpage>7</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.053033</pub-id><pub-id pub-id-type="pmid">33947203</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Jordan E, Peterson L, Ai T, et al. Evidence-Based assessment of genes in dilated cardiomyopathy. Circulation. 2021;144:7&#x02013;19.<pub-id pub-id-type="pmid">33947203</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Gigli</surname><given-names>M</given-names></name><name><surname>Merlo</surname><given-names>M</given-names></name><name><surname>Graw</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>2019</year><volume>74</volume><fpage>1480</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.06.072</pub-id><pub-id pub-id-type="pmid">31514951</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Gigli M, Merlo M, Graw SL, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2019;74:1480&#x02013;90.<pub-id pub-id-type="pmid">31514951</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Corden</surname><given-names>B</given-names></name><name><surname>Jarman</surname><given-names>J</given-names></name><name><surname>Whiffin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Association of Titin-Truncating genetic variants with Life-threatening cardiac arrhythmias in patients with dilated cardiomyopathy and implanted defibrillators</article-title><source>JAMA Netw Open</source><year>2019</year><volume>2</volume><fpage>e196520</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.6520</pub-id><pub-id pub-id-type="pmid">31251381</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Corden B, Jarman J, Whiffin N, et al. Association of Titin-Truncating genetic variants with Life-threatening cardiac arrhythmias in patients with dilated cardiomyopathy and implanted defibrillators. JAMA Netw Open. 2019;2:e196520.<pub-id pub-id-type="pmid">31251381</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Florwick A, Dharmaraj T, Jurgens J, Valle D, Wilson KL. LMNA sequences of 60,706 unrelated individuals reveal 132 novel missense variants in A-Type lamins and suggest a link between variant p.G602S and type 2 diabetes. Front Genet. 2017;8.</mixed-citation></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Desgrouas</surname><given-names>C</given-names></name><name><surname>Varlet</surname><given-names>A-A</given-names></name><name><surname>Dutour</surname><given-names>A</given-names></name><etal/></person-group><article-title>Unraveling LMNA mutations in metabolic syndrome: cellular phenotype and clinical pitfalls</article-title><source>Cells</source><year>2020</year><volume>9</volume><fpage>310</fpage><pub-id pub-id-type="doi">10.3390/cells9020310</pub-id><pub-id pub-id-type="pmid">32012908</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Desgrouas C, Varlet A-A, Dutour A, et al. Unraveling LMNA mutations in metabolic syndrome: cellular phenotype and clinical pitfalls. Cells. 2020;9:310.<pub-id pub-id-type="pmid">32012908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Huang B, Lin H, Zhang Q et al. Identification of shared fatty acid metabolism related signatures in dilated cardiomyopathy and myocardial infarction. Future Sci OA. 2023;9.</mixed-citation></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Exploring the role of obesity in dilated cardiomyopathy based on Bio-informatics analysis</article-title><source>J Cardiovasc Dev Dis</source><year>2022</year><volume>9</volume><fpage>462</fpage><pub-id pub-id-type="pmid">36547458</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Wang X, Liu W, Li H, Ding J, Feng Y, Chen Z. Exploring the role of obesity in dilated cardiomyopathy based on Bio-informatics analysis. J Cardiovasc Dev Dis. 2022;9:462.<pub-id pub-id-type="pmid">36547458</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>SL</given-names></name><name><surname>Henry</surname><given-names>A</given-names></name><name><surname>Cannie</surname><given-names>D</given-names></name><etal/></person-group><article-title>Genome-wide association analysis provides insights into the molecular etiology of dilated cardiomyopathy</article-title><source>Nat Genet</source><year>2024</year><volume>56</volume><fpage>2646</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/s41588-024-01952-y</pub-id><pub-id pub-id-type="pmid">39572783</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Zheng SL, Henry A, Cannie D, et al. Genome-wide association analysis provides insights into the molecular etiology of dilated cardiomyopathy. Nat Genet. 2024;56:2646&#x02013;58.<pub-id pub-id-type="pmid">39572783</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Antonopoulos AS, Panagiotopoulos I, Terentes-Printzios D et al. Relationship between obesity and hypertrophic or dilated cardiomyopathy: the role of sex. Clin Obes. 2024;14.</mixed-citation></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname><given-names>BP</given-names></name><name><surname>Gulati</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sex- and age&#x02010;based differences in the natural history and outcome of dilated cardiomyopathy</article-title><source>Eur J Heart Fail</source><year>2018</year><volume>20</volume><fpage>1392</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1002/ejhf.1216</pub-id><pub-id pub-id-type="pmid">29862606</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Halliday BP, Gulati A, Ali A, et al. Sex- and age&#x02010;based differences in the natural history and outcome of dilated cardiomyopathy. Eur J Heart Fail. 2018;20:1392&#x02013;400.<pub-id pub-id-type="pmid">29862606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Cannata</surname><given-names>A</given-names></name><name><surname>Manca</surname><given-names>P</given-names></name><name><surname>Nuzzi</surname><given-names>V</given-names></name><etal/></person-group><article-title>Sex-Specific prognostic implications in dilated cardiomyopathy after left ventricular reverse remodeling</article-title><source>J Clin Med</source><year>2020</year><volume>9</volume><fpage>2426</fpage><pub-id pub-id-type="doi">10.3390/jcm9082426</pub-id><pub-id pub-id-type="pmid">32751220</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Cannata A, Manca P, Nuzzi V, et al. Sex-Specific prognostic implications in dilated cardiomyopathy after left ventricular reverse remodeling. J Clin Med. 2020;9:2426.<pub-id pub-id-type="pmid">32751220</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Long C, Liu X, Xiong Q, Su Y, Hong K. Sex differences in dilated cardiomyopathy prognosis A systematic review and Meta-analysis. Int Heart J. 2022;63.</mixed-citation></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Cannat&#x000e0;</surname><given-names>A</given-names></name><name><surname>Fabris</surname><given-names>E</given-names></name><name><surname>Merlo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sex differences in the Long-term prognosis of dilated cardiomyopathy</article-title><source>Can J Cardiol</source><year>2020</year><volume>36</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2019.05.031</pub-id><pub-id pub-id-type="pmid">31515085</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Cannat&#x000e0; A, Fabris E, Merlo M, et al. Sex differences in the Long-term prognosis of dilated cardiomyopathy. Can J Cardiol. 2020;36:37&#x02013;44.<pub-id pub-id-type="pmid">31515085</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>R</given-names></name><name><surname>Buchan</surname><given-names>R</given-names></name><name><surname>Frenneaux</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sex differences in the clinical presentation and natural history of dilated cardiomyopathy</article-title><source>JACC Heart Fail</source><year>2024</year><volume>12</volume><fpage>352</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.jchf.2023.10.009</pub-id><pub-id pub-id-type="pmid">38032570</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Owen R, Buchan R, Frenneaux M, et al. Sex differences in the clinical presentation and natural history of dilated cardiomyopathy. JACC Heart Fail. 2024;12:352&#x02013;63.<pub-id pub-id-type="pmid">38032570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Nassiri</surname><given-names>S</given-names></name><name><surname>Van de Bovenkamp</surname><given-names>AA</given-names></name><name><surname>Remmelzwaal</surname><given-names>S</given-names></name><name><surname>Sorea</surname><given-names>O</given-names></name><name><surname>de Man</surname><given-names>F</given-names></name><name><surname>Handoko</surname><given-names>ML</given-names></name></person-group><article-title>Effects of Trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis</article-title><source>Open Heart</source><year>2024</year><volume>11</volume><fpage>e002579</fpage><pub-id pub-id-type="doi">10.1136/openhrt-2023-002579</pub-id><pub-id pub-id-type="pmid">38719498</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Nassiri S, Van de Bovenkamp AA, Remmelzwaal S, Sorea O, de Man F, Handoko ML. Effects of Trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis. Open Heart. 2024;11:e002579.<pub-id pub-id-type="pmid">38719498</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Palmiero</surname><given-names>G</given-names></name><name><surname>Cesaro</surname><given-names>A</given-names></name><name><surname>Vetrano</surname><given-names>E</given-names></name><etal/></person-group><article-title>Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>5863</fpage><pub-id pub-id-type="doi">10.3390/ijms22115863</pub-id><pub-id pub-id-type="pmid">34070765</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Palmiero G, Cesaro A, Vetrano E, et al. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci. 2021;22:5863.<pub-id pub-id-type="pmid">34070765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Usman</surname><given-names>MS</given-names></name><name><surname>Khan</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis</article-title><source>ESC Heart Fail</source><year>2020</year><volume>7</volume><fpage>3298</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13169</pub-id><pub-id pub-id-type="pmid">33586910</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Butler J, Usman MS, Khan MS, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail. 2020;7:3298&#x02013;309.<pub-id pub-id-type="pmid">33586910</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name></person-group><article-title>Effect of Dapagliflozin on left ventricular structure and function in patients with non-ischemic dilated cardiomyopathy: an observational study</article-title><source>Medicine</source><year>2024</year><volume>103</volume><fpage>e37579</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000037579</pub-id><pub-id pub-id-type="pmid">38552078</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Hong J, Huang L, Jin N, Zhao X, Hu J. Effect of Dapagliflozin on left ventricular structure and function in patients with non-ischemic dilated cardiomyopathy: an observational study. Medicine. 2024;103:e37579.<pub-id pub-id-type="pmid">38552078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Usman</surname><given-names>MS</given-names></name><name><surname>Siddiqi</surname><given-names>TJ</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations</article-title><source>J Am Coll Cardiol</source><year>2023</year><volume>81</volume><fpage>2377</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2023.04.034</pub-id><pub-id pub-id-type="pmid">37344038</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Usman MS, Siddiqi TJ, Anker SD, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81:2377&#x02013;87.<pub-id pub-id-type="pmid">37344038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Deanfield</surname><given-names>J</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Scirica</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial</article-title><source>Lancet</source><year>2024</year><volume>404</volume><fpage>773</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)01498-3</pub-id><pub-id pub-id-type="pmid">39181597</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404:773&#x02013;86.<pub-id pub-id-type="pmid">39181597</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Buz</surname><given-names>B-F</given-names></name><name><surname>Negrean</surname><given-names>RA</given-names></name><name><surname>Caruntu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Systematic review of left ventricular remodeling in response to hypoglycemic medications: assessing changes in End-Systolic and End-Diastolic diameters</article-title><source>Biomedicines</source><year>2024</year><volume>12</volume><fpage>1791</fpage><pub-id pub-id-type="doi">10.3390/biomedicines12081791</pub-id><pub-id pub-id-type="pmid">39200254</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Buz B-F, Negrean RA, Caruntu F, et al. Systematic review of left ventricular remodeling in response to hypoglycemic medications: assessing changes in End-Systolic and End-Diastolic diameters. Biomedicines. 2024;12:1791.<pub-id pub-id-type="pmid">39200254</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Odigwe</surname><given-names>C</given-names></name><name><surname>Mulyala</surname><given-names>R</given-names></name><name><surname>Malik</surname><given-names>H</given-names></name><etal/></person-group><article-title>Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on semaglutide</article-title><source>Am Heart J Plus: Cardiol Res Pract</source><year>2025</year><volume>52</volume><fpage>100518</fpage></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Odigwe C, Mulyala R, Malik H, et al. Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on semaglutide. Am Heart J Plus: Cardiol Res Pract. 2025;52:100518.</mixed-citation></citation-alternatives></ref></ref-list></back></article>